SEMPREX D is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Endo Pharmaceuticals Inc.. The primary component is Acrivastine; Pseudoephedrine Hydrochloride.
| Product ID | 52244-404_21d2a8a6-108c-4c1d-b1ee-c14f6f2dadc6 | 
| NDC | 52244-404 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | SEMPREX D | 
| Generic Name | Acrivastine And Pseudoephedrine Hydrochloride | 
| Dosage Form | Capsule | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2012-01-26 | 
| Marketing End Date | 2020-12-31 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA019806 | 
| Labeler Name | Endo Pharmaceuticals Inc. | 
| Substance Name | ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE | 
| Active Ingredient Strength | 8 mg/1; mg/1 | 
| Pharm Classes | Histamine H1 Receptor Antagonists [MoA],Histamine-1 Receptor Antagonist [EPC],Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] | 
| NDC Exclude Flag | N | 
| Marketing Start Date | 2012-01-26 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | NDA | 
| Application Number | NDA019806 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | EA | 
| Marketing Start Date | 2012-01-26 | 
| Ingredient | Strength | 
|---|---|
| ACRIVASTINE | 8 mg/1 | 
| SPL SET ID: | d86c6a13-9e5f-43c2-92f5-c7ed7bfcedfc | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() SEMPREX  78429596  3023249 Live/Registered  | 
        ACTIENT PHARMACEUTICALS LLC  2004-06-03  | 
![]() SEMPREX  74338456  1879087 Dead/Cancelled  | 
        Burroughs Wellcome Co.  1992-12-09  | 
![]() SEMPREX  73514851  1421747 Live/Registered  | 
        SEMPREX CORPORATION  1984-12-24  |